Report cover image

CRDMO Market

Publisher BlueWeave Consulting
Published Oct 06, 2025
Length 550 Pages
SKU # BLWC20706876

Description

CRDMO Market, By Service Type (Contract Research, Contract Development, Contract Manufacturing); By Therapeutic Area (Oncology, Infectious Diseases, Cardiovascular Disorders); By Molecule Type (Small Molecules, Biologics, Cell & Gene Therapies); By End User (Pharmaceutical Companies, Biotechnology Firms, Academic & Research Institutes); By Region (North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA)), Global Trend Analysis, Competitive Landscape & Forecast, 2019–2031Global CRDMO Market Size to Set to Surpass USD 409 Billion by 2031

Global CRDMO (Contract Research, Development, and Manufacturing Organization) Market is booming primarily due to rising outsourcing trends, rapid adoption of technological innovations, regulatory support, and increasing investments in biopharma R&D programs.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global CRDMO (Contract Research, Development, and Manufacturing Organization) Market size by value at USD 241.24 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Global CRDMO Market size to expand at a significant CAGR of 7.85%, reaching a value of USD 409.44 billion. The growth of Global CRDMO Market is propelled by several key factors, including a rising demand for personalized medicine and biologics, increased outsourcing by biopharmaceutical companies to reduce costs and accelerate timelines, and technological advancements in drug discovery and development. Regulatory support for faster approvals and growing investments in R&D also contribute to the expansion of Global CRDMO Market significantly. Additionally, the expansion of small and mid-sized biopharma firms and the need for integrated, end-to-end services are making CRDMOs strategic partners in the evolving healthcare landscape.

Opportunity – Adoption of Advanced Technologies in Drug Development

Global CRDMO Market is witnessing robust growth driven by the rapid adoption of cutting-edge technologies in the drug development process. Innovations such as AI-driven molecule screening, high-throughput automation, and advanced bioinformatics are accelerating discovery timelines and improving precision. These advancements enable faster, cost-effective development of complex biologics and personalized therapies. Integration of digital platforms and cloud-based data analytics further enhances collaboration and scalability, positioning CRDMOs as vital partners in modern pharmaceutical innovation and global healthcare transformation.

Oncology Segment Holds Largest Market Share of Global CDRMO Market

The oncology segment stands out as the largest and most dominant therapeutic area in Global CRDMO Market, due to the rising incidence of various cancer types across the world and the increasing complexity of oncology drug development, which demands specialized expertise and infrastructure. Oncology accounts for approximately 30% of the total CRDMO market share, surpassing Infectious Diseases and Cardiovascular Disorders segments. The high demand for biologics, cytotoxics, and targeted therapies further fuels growth, making oncology a strategic focus for CRDMO service providers.

Impact of Escalating Geopolitical Tensions on Global CRDMO Market

Escalating geopolitical tensions are reshaping Global CRDMO Market by disrupting supply chains, increasing regulatory scrutiny, and creating uncertainty in cross-border collaborations. Trade restrictions and export controls hinder material sourcing and technology transfer, while rising nationalism pressures companies to localize operations. These dynamics compel CRDMOs to diversify geographic footprints, invest in risk mitigation strategies, and strengthen regional partnerships. Although challenges persist, firms with agile operations and global adaptability are better positioned to navigate instability and sustain growth.

Competitive Landscape

Global CRDMO Market is highly fragmented, with numerous players serving the market. Major companies dominating the market are Thermo Fisher Scientific, Lonza Group, Catalent Inc., WuXi AppTec, Samsung Biologics, Charles River Laboratories, Labcorp Drug Development, Syngene International, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, Recipharm AB, Curia Global, Jubilant Biosys, Asymchem Laboratories, and Eurofins Scientific. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisitions to expand their customer reach and gain a competitive edge over their competitors in Global CRDMO Market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and Global CRDMO Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global CRDMO Market, along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

550 Pages
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentations
2. Executive Summary
3. Global CRDMO Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Rising Demand for Biopharmaceuticals
3.2.1.2. Increasing Outsourcing by Pharma Companies
3.2.1.3. Expansion of Oncology Drug Development
3.2.2. Restraints
3.2.2.1. High Cost of Biologics Manufacturing
3.2.2.2. Regulatory Compliance Complexities
3.2.2.3. Limited Skilled Workforce Availability
3.2.3. Opportunities
3.2.3.1. Technological Advancements in Drug Development
3.2.3.2. Emerging Markets Driving Healthcare Demand
3.2.4. Challenges
3.2.4.1. Integration Across Global Supply Chains
3.2.4.2. Managing Intellectual Property Risks
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter’s Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global CRDMO Market: Marketing Strategies
5. Global CRDMO Market Overview
5.1. Market Size & Forecast, 2019–2030
5.1.1. By Value (USD Million)
5.2. Market Share and Forecast
5.2.1. By Service Type
5.2.1.1. Contract Research
5.2.1.2. Contract Development
5.2.1.3. Contract Manufacturing
5.2.2. By Therapeutic Area
5.2.2.1. Oncology
5.2.2.2. Infectious Diseases
5.2.2.3. Cardiovascular Disorders
5.2.3. By Molecule Type
5.2.3.1. Small Molecules
5.2.3.2. Biologics
5.2.3.3. Cell & Gene Therapies
5.2.4. By End User
5.2.4.1. Pharmaceutical Companies
5.2.4.2. Biotechnology Firms
5.2.4.3. Academic & Research Institutes
5.2.5. By Region
5.2.5.1. North America
5.2.5.2. Europe
5.2.5.3. Asia Pacific (APAC)
5.2.5.4. Latin America (LATAM)
5.2.5.5. Middle East and Africa (MEA)
6. North America CRDMO Market
6.1. Market Size & Forecast, 2019–2030
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Service Type
6.2.2. By Therapeutic Area
6.2.3. By Molecule Type
6.2.4. By End User
6.2.5. By Country
6.2.5.1. United States
6.2.5.1.1. By Service Type
6.2.5.1.2. By Therapeutic Area
6.2.5.1.3. By Molecule Type
6.2.5.1.4. By End User
6.2.5.2. Canada
6.2.5.2.1. By Service Type
6.2.5.2.2. By Therapeutic Area
6.2.5.2.3. By Molecule Type
6.2.5.2.4. By End User
7. Europe CRDMO Market
7.1. Market Size & Forecast, 2019–2030
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Service Type
7.2.2. By Therapeutic Area
7.2.3. By Molecule Type
7.2.4. By End User
7.2.5. By Country
7.2.5.1. Germany
7.2.5.1.1. By Service Type
7.2.5.1.2. By Therapeutic Area
7.2.5.1.3. By Molecule Type
7.2.5.1.4. By End User
7.2.5.2. United Kingdom
7.2.5.2.1. By Service Type
7.2.5.2.2. By Therapeutic Area
7.2.5.2.3. By Molecule Type
7.2.5.2.4. By End User
7.2.5.3. Italy
7.2.5.3.1. By Service Type
7.2.5.3.2. By Therapeutic Area
7.2.5.3.3. By Molecule Type
7.2.5.3.4. By End User
7.2.5.4. France
7.2.5.4.1. By Service Type
7.2.5.4.2. By Therapeutic Area
7.2.5.4.3. By Molecule Type
7.2.5.4.4. By End User
7.2.5.5. Spain
7.2.5.5.1. By Service Type
7.2.5.5.2. By Therapeutic Area
7.2.5.5.3. By Molecule Type
7.2.5.5.4. By End User
7.2.5.6. Belgium
7.2.5.6.1. By Service Type
7.2.5.6.2. By Therapeutic Area
7.2.5.6.3. By Molecule Type
7.2.5.6.4. By End User
7.2.5.7. Russia
7.2.5.7.1. By Service Type
7.2.5.7.2. By Therapeutic Area
7.2.5.7.3. By Molecule Type
7.2.5.7.4. By End User
7.2.5.8. The Netherlands
7.2.5.8.1. By Service Type
7.2.5.8.2. By Therapeutic Area
7.2.5.8.3. By Molecule Type
7.2.5.8.4. By End User
7.2.5.9. Rest of Europe
7.2.5.9.1. By Service Type
7.2.5.9.2. By Therapeutic Area
7.2.5.9.3. By Molecule Type
7.2.5.9.4. By End User
8. Asia Pacific CRDMO Market
8.1. Market Size & Forecast, 2019–2030
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Service Type
8.2.2. By Therapeutic Area
8.2.3. By Molecule Type
8.2.4. By End User
8.2.5. By Country
8.2.5.1. China
8.2.5.1.1. By Service Type
8.2.5.1.2. By Therapeutic Area
8.2.5.1.3. By Molecule Type
8.2.5.1.4. By End User
8.2.5.2. India
8.2.5.2.1. By Service Type
8.2.5.2.2. By Therapeutic Area
8.2.5.2.3. By Molecule Type
8.2.5.2.4. By End User
8.2.5.3. Japan
8.2.5.3.1. By Service Type
8.2.5.3.2. By Therapeutic Area
8.2.5.3.3. By Molecule Type
8.2.5.3.4. By End User
8.2.5.4. South Korea
8.2.5.4.1. By Service Type
8.2.5.4.2. By Therapeutic Area
8.2.5.4.3. By Molecule Type
8.2.5.4.4. By End User
8.2.5.5. Australia & New Zealand
8.2.5.5.1. By Service Type
8.2.5.5.2. By Therapeutic Area
8.2.5.5.3. By Molecule Type
8.2.5.5.4. By End User
8.2.5.6. Indonesia
8.2.5.6.1. By Service Type
8.2.5.6.2. By Therapeutic Area
8.2.5.6.3. By Molecule Type
8.2.5.6.4. By End User
8.2.5.7. Malaysia
8.2.5.7.1. By Service Type
8.2.5.7.2. By Therapeutic Area
8.2.5.7.3. By Molecule Type
8.2.5.7.4. By End User
8.2.5.8. Singapore
8.2.5.8.1. By Service Type
8.2.5.8.2. By Therapeutic Area
8.2.5.8.3. By Molecule Type
8.2.5.8.4. By End User
8.2.5.9. Vietnam
8.2.5.9.1. By Service Type
8.2.5.9.2. By Therapeutic Area
8.2.5.9.3. By Molecule Type
8.2.5.9.4. By End User
8.2.5.10. Rest of APAC
8.2.5.10.1. By Service Type
8.2.5.10.2. By Therapeutic Area
8.2.5.10.3. By Molecule Type
8.2.5.10.4. By End User
9. Latin America CRDMO Market
9.1. Market Size & Forecast, 2019–2030
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Service Type
9.2.2. By Therapeutic Area
9.2.3. By Molecule Type
9.2.4. By End User
9.2.5. By Country
9.2.5.1. Brazil
9.2.5.1.1. By Service Type
9.2.5.1.2. By Therapeutic Area
9.2.5.1.3. By Molecule Type
9.2.5.1.4. By End User
9.2.5.2. Mexico
9.2.5.2.1. By Service Type
9.2.5.2.2. By Therapeutic Area
9.2.5.2.3. By Molecule Type
9.2.5.2.4. By End User
9.2.5.3. Argentina
9.2.5.3.1. By Service Type
9.2.5.3.2. By Therapeutic Area
9.2.5.3.3. By Molecule Type
9.2.5.3.4. By End User
9.2.5.4. Peru
9.2.5.4.1. By Service Type
9.2.5.4.2. By Therapeutic Area
9.2.5.4.3. By Molecule Type
9.2.5.4.4. By End User
9.2.5.5. Rest of LATAM
9.2.5.5.1. By Service Type
9.2.5.5.2. By Therapeutic Area
9.2.5.5.3. By Molecule Type
9.2.5.5.4. By End User
10. Middle East & Africa CRDMO Market
10.1. Market Size & Forecast, 2019–2030
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1. By Service Type
10.2.2. By Therapeutic Area
10.2.3. By Molecule Type
10.2.4. By End User
10.2.5. By Country
10.2.5.1. Saudi Arabia
10.2.5.1.1. By Service Type
10.2.5.1.2. By Therapeutic Area
10.2.5.1.3. By Molecule Type
10.2.5.1.4. By End User
10.2.5.2. UAE
10.2.5.2.1. By Service Type
10.2.5.2.2. By Therapeutic Area
10.2.5.2.3. By Molecule Type
10.2.5.2.4. By End User
10.2.5.3. Qatar
10.2.5.3.1. By Service Type
10.2.5.3.2. By Therapeutic Area
10.2.5.3.3. By Molecule Type
10.2.5.3.4. By End User
10.2.5.4. Kuwait
10.2.5.4.1. By Service Type
10.2.5.4.2. By Therapeutic Area
10.2.5.4.3. By Molecule Type
10.2.5.4.4. By End User
10.2.5.5. South Africa
10.2.5.5.1. By Service Type
10.2.5.5.2. By Therapeutic Area
10.2.5.5.3. By Molecule Type
10.2.5.5.4. By End User
10.2.5.6. Nigeria
10.2.5.6.1. By Service Type
10.2.5.6.2. By Therapeutic Area
10.2.5.6.3. By Molecule Type
10.2.5.6.4. By End User
10.2.5.7. Algeria
10.2.5.7.1. By Service Type
10.2.5.7.2. By Therapeutic Area
10.2.5.7.3. By Molecule Type
10.2.5.7.4. By End User
10.2.5.8. Rest of MEA
10.2.5.8.1. By Service Type
10.2.5.8.2. By Therapeutic Area
10.2.5.8.3. By Molecule Type
10.2.5.8.4. By End User
11. Competitive Landscape
11.1. List of Key Players and Their Offerings
11.2. Global CRDMO Market Share Analysis, 2023
11.3. Competitive Benchmarking, By Operating Parameters
11.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
12. Impact of Escalating Geopolitical Tensions on Global CRDMO Market
13. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
13.1. Thermo Fisher Scientific
13.2. Lonza Group
13.3. Catalent Inc.
13.4. WuXi AppTec
13.5. Samsung Biologics
13.6. Charles River Laboratories
13.7. Labcorp Drug Development
13.8. Syngene International
13.9. Boehringer Ingelheim
13.10. Fujifilm Diosynth Biotechnologies
13.11. Recipharm AB
13.12. Curia Global
13.13. Jubilant Biosys
13.14. Asymchem Laboratories
13.15. Eurofins Scientific
13.16. Other Prominent Players
14. Key Strategic Recommendations
15. Research Methodology
15.1.Qualitative Research
15.1.1.Primary & Secondary Research
15.2. Quantitative Research
15.3. Market Breakdown & Data Triangulation
15.3.1.Secondary Research
15.3.2.Primary Research
15.4. Breakdown of Primary Research Respondents, By Region
15.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us